top646 slot

top646 slot ENERGY SERVICES OF AMERICA COMPLETES ACQUISITIONBlack Friday is upon us—it's basically a whole season now, not just a day—and the deals are rolling in. I'll keep updating this post with the best bargains on fitness equipment, but I've already found a ton of deep discounts on spin bikes, adjustable dumbbells, and more. (It's also worth checking out the deals on Garmin watches if you're looking for something to track your workouts.) Deals on Powerblock and Bowflex adjustable dumbbells Several of my picks for the best adjustable dumbbells are on sale today. The Powerblock Elite EXP Stage 1 , which goes from 5 to 50 pounds, is on sale for $299/pair at Amazon, normally $449—or $199 for a single, at Walmart. Its Stage 2 and Stage 3 expansion kits are also on sale, both $142.90, down from $169. Each kit adds 20 pounds, so with both you can have a pair of 90 pound dumbbells. The Bowflex SelectTech 552 are on sale for $379/pair, from a list price of $549. They sometimes go for a bit less than list price, but the sale price here is lower than I've seen it all year. Deals on Peloton and NordicTrack spin bikes Peloton has gotten into the habit of offering sweet deals on its bikes on all the major shopping holidays, so of course there's a nice Black Friday sale going. The basic model Bike is $1,295 (down from $1,445) and the fancier Bike+ is $1,995 (normally $2,495). Of the two, the Bike+ is the better sale compared to historical price data, but ultimately you should choose based on which fits your needs better. I have a guide here to help you decide between the Bike and the Bike+ . Peloton isn't the only game in town when it comes to higher-end spin bikes, though. NordicTrack's Commercial Studio Cycle is $1,274.98 (down from $1,499.99) for the S22i model. It has the same size screen as the Peloton Bike, a swiveling mount for the screen like the Bike+, and automatic resistance like the Bike+. (Like Peloton's offerings, it also requires a monthly subscription to access its digital features—but in this case, you'll pay $39/month rather than $44.) Deals on Theragun and Hyperice massage guns A massage gun is a great tool for whenever you feel like you'd enjoy being punched repeatedly, but therapeutically. (As I discovered when I tried one out, I do not enjoy this —but many people do.) Some of the big brands have models on sale right now. The Hypervolt Go is $99 right now (normally $129) and it's available in both white and black. And the triangular Theragun Mini , normally $199, is now $149 or $159 depending on your color preference. Desert rose and black are the more inexpensive ones at the moment. Deals on barbells, dumbbells, and other useful heavy things Rogue Fitness is running a "Matte Black November" sale with discounts on a variety of items, some for limited times or with limited stock. One great deal that caught my eye (and which should be available through Cyber Monday) is the 15 kg Bella bar for $205 (normally $235). This is a 15 kilogram Olympic barbell, great for anyone who does Crossfit or olympic weightlifting, especially if you compete in the women's or youth divisions. (And if you're not clear on why there's a separate bar for women in these sports, I have a whole explainer here .) There are also bumper plates on sale from various retailers, and I'd like to highlight these basic 45-pound bumpers from GIKPAL. Bumpers are great for Olympic lifts, but also for deadlifts or anything else where you'd like to protect your floor and your ears a bit. These are now $116 for a pair , normally $179.With Bill Skarsgård as the "horrible old vampire", Robert Eggers's remake of FW Murnau's silent 1922 classic stars Lily-Rose Depp, Nicholas Hoult, and has its "share of gruesome shocks". Many people have seen plenty of vampire films , but what if we hadn't seen any? What if we'd never heard of Dracula, and we had only the vaguest idea of what a vampire might be? Welcome to the world of Nosferatu, written and directed by Robert Eggers. A remake of FW Murnau's silent classic – which in itself was a fairly faithful, if unofficial, adaptation of Bram Stoker's Dracula – this is a film that restores the mystery and magic to the concept of an undead bloodsucker by stripping away all of the vampire clichés that have built up since Murnau's original was released in 1922. Eggers is the ideal man for the job. Before he made The Witch, The Lighthouse and The Northman , he was so obsessed with Murnau's Nosferatu that he staged it as a school play when he was a teenager. He is also known for putting his own stamp on horror films by shooting them as if they were arthouse period dramas – and that's what he does here. The costumes and props are all true to the 19th-Century setting, the spectacular outdoor scenes are shot on location in the Czech Republic and Romania, and some of the indoor scenes are illuminated only by candlelight. At the start, when a top-hatted Thomas Hutter is hurrying through the bustling streets to his musty office, you could easily mistake him for Bob Cratchit in A Christmas Carol . If you're not familiar with the name Hutter, that's because the makers of 1922's Nosferatu changed some of the details of Stoker's story, in a vain attempt to get around copyright issues ( Stoker's widow sued them, anyway ): much of the action takes place in the fictional German harbour town of Wisborg in 1838, rather than London in the 1890s. But the outline of the plot is unmistakably Stoker's. Hutter (Nicholas Hoult) is a callow solicitor who works for a cackling weirdo named Knock (Simon McBurney on hilariously frenzied form). In order to secure a promotion, Hutter agrees to journey to distant Transylvania for a meeting with a certain count. His new bride Ellen (Lily-Rose Depp) begs him not to take the trip, but Hutter insists, and leaves Ellen in the care of his wealthy friend Harding (Aaron Taylor-Johnson) and Harding's wife Anna (Emma Corrin). Before long, they'll need the help of a diligent doctor named Sievers (Ralph Ineson), and his mentor, a professor of the occult who was called Van Helsing in Stoker's novel, but is renamed Von Franz (Willem Dafoe) in Nosferatu. Hutter's lone horse ride through wintry forests and over rocky mountains is full of breathtakingly beautiful vistas, and Eggers makes the terrain seem so wild and inhospitable that Hutter would have earned his promotion whatever the destination. But, of course, the destination is a crumbling castle occupied by the Dracula-like Count Orlok. He is played by Bill Skarsgård (It, The Crow, John Wick: Chapter Four ), not that anyone could recognise him underneath all the prosthetic make-up and the layers of heavy clothing. Eggers wisely keeps him at a distance and in the shadows during his first scenes, but the creature we're eventually shown is more like a maggoty walking corpse than the suave seducer seen in most vampire films. Rumoured to be a sorcerer who sold his soul to Satan in return for eternal life, Orlok has the fashion sense of Vlad the Impaler, a booming, vowel-mangling voice which makes it sound as if he is always at the far end of a tunnel, and the loudest wheeze since Darth Vader. He may never be as iconic as his 1922 counterpoint, and he doesn't seem as tragically lonely as he was when Max Schreck played him in Murnau's film, but the imposing (and decomposing) fiend that Eggers and Skarsgård have created is a Dracula/ Orlok unlike any other, which is quite an achievement after more than a century of on-screen vampires. When Orlok begins his reign of terror in Wisborg, Eggers seems to be influenced by The Exorcist and Alien , two films that visit unearthly ordeals on grounded human characters. True, there are smatterings of camp humour, some more deliberate than others. Dafoe is enjoying himself a little too much as a hearty, moustache-twirling eccentric who goes around chirping: "The night demon has supped of your good wife's blood." And Taylor-Johnson's strained attempt at an upper-crust English accent may have you chuckling through the film's gravest scenes. But overall, Eggers takes his doom-laden tale bracingly seriously. Almost everyone commits themselves to the mood of gothic melodrama, and no one makes any ironic wisecracks about garlic or bats. Hoult is especially poignant as Hutter, a would-be hero who is reduced to a feverish wreck by his Transylvanian excursion – and by his own desperate desire to move up to a higher social and economic class. Depp, meanwhile, is a revelation as the troubled Ellen. The uncanny connection between the count and the heroine echoes the one in Francis Ford Coppola's Dracula film, but Eggers places it at the dark heart of Nosferatu. Ellen is deeply in love with her husband, but she has been haunted for years by nightmarish yet erotic visions of another man. As Orlok preys on the people of Wisborg, she is tormented by the question of whether he is an actual monster or just the embodiment of her own emotional instability and unfulfilled yearnings. In contrast with most vampire films, then, this one is about sex rather than sexiness, ie, it's not about vampires being devilishly attractive, it's about men controlling women's bodies. One shrewd point made by Eggers is that the doctors of the period could be vampire-like themselves. When Ellen starts to have fits, Sievers's diagnosis isn't that she is possessed by an evil spirit, but that this hysterical female simply has "too much blood" in her veins. Still, however multi-layered and innovative Nosferatu is, there's no escaping the fact that it's still a Dracula film, which means that familiar things keep happening to familiar characters, and the inevitability of it all makes it more sad than scary. As Eggers proceeds steadily and methodically through the events in Murnau's masterpiece, you may admire the intelligence and painstaking craft that has gone into it, but you may also have the feeling that you're watching actors playing time-honoured roles rather than real people in mortal danger. Horror fans needn't worry, though: Nosferatu has its share of gruesome shocks. And after so many years of cool teen vampires, it's refreshing to see a horrible old vampire again. But what really separates Eggers' Nosferatu from the flock is how deeply it explores the images and themes of vampire lore. There aren't many Dracula films that give you so much to sink your teeth into. ★★★★☆ Nosferatu is released on 25 December in the US and 1 Jan in the UK. -- If you liked this story, sign up for The Essential List newsletter – a handpicked selection of features, videos and can't-miss news delivered to your inbox every Friday. For more Culture stories from the BBC, follow us on Facebook , X and Instagram .

Provident Bancorp, Inc. Adopts Stock Repurchase Program

Onyiah 5-13 3-4 13, Suarez 4-12 3-4 14, Krimili 4-14 5-6 15, Twidale 8-13 1-2 20, Williams 0-1 3-4 3, Ackerman 0-2 1-2 1, Abigor 2-3 0-2 4, Donez 1-1 0-0 2, Maul 0-0 0-0 0, Totals 24-59 16-24 72 Tate 2-4 0-0 5, VanSlooten 3-12 7-14 13, Ayrault 7-20 6-8 22, Hallock 5-15 3-4 15, Shumate 1-4 0-0 3, Sotelo 1-1 1-2 3, Blair 0-0 0-0 0, Hampton 4-4 0-0 10, Kimball 0-1 0-0 0, Simmons 2-9 3-5 7, Totals 25-70 20-33 78 3-Point Goals_California 8-22 (Suarez 3-7, Krimili 2-7, Twidale 3-8), Michigan St. 8-20 (Tate 1-2, Ayrault 2-6, Hallock 2-4, Shumate 1-4, Hampton 2-2, Kimball 0-1, Simmons 0-1). Assists_California 14 (Krimili 5), Michigan St. 13 (Simmons 3). Fouled Out_California Onyiah, Suarez, Michigan St. Tate. Rebounds_California 46 (Suarez 11), Michigan St. 42 (Ayrault 9). Total Fouls_California 24, Michigan St. 18. Technical Fouls_California Krimili 1, Michigan St. Tate 1, Team 1. A_325.

In this environment, you can land some pretty solid high-yielders (think yields at or north of 6%) without running face-first into an imminent dividend or distribution reduction. Indeed, chasing yield is often a precarious thing to do, especially for retirees who want more passive income to fund their retirement expenses. Even though interest rates have come down quite a bit, they’re still a tad high. And if the Bank of Canada suddenly stops cutting rates (it’s a possibility if tit-for-tat tariffs and other trade risks are in the near future), perhaps the high-yielding REITs (real estate investment trusts) and their high yields could prove smart bets today. As always, though, I’d never encourage investors to make moves based on where they expect rates will be in the future. Further, unpredictable things can happen (maybe Trump will reach a new trade deal, and tariffs won’t have a chance to happen), making it ultra-challenging to profit from macroeconomic events. In any case, here are three great REIT plays that investors may wish to check out if they seek yields over 6% and a good shot at longer-term appreciation. SmartCentres REIT First up, we have an underrated retail REIT in ( ), which has a yield of 7.19%. Indeed, the distribution may be a lofty commitment, but it’s one that I believe is more sustainable than it looks. As one of the higher-yielding REITs that kept paying distributions during lockdowns, I’d argue that Smart’s payout is safer than the adjusted funds from operations (AFFO) payout ratio would suggest. If its distribution can make it through the worst of a pandemic, I’d argue it can also fare well through a mild economic or period of stagnation. Indeed, it’s easy to forget just how resilient the REIT and its distribution were through one of the worst market plunges in recent memory! Further, SmartCentres stands out as a REIT that could get back on the growth track once rates finally do fall significantly. Residential real estate is just one area that could help Smart enhance its growth profile. Lower borrowing costs may be the boost the REIT needs to sustain a rally toward prior highs. Either way, it’s only smart to consider the name if you seek a secure but still hefty yield. H&R REIT ( ) shares are yielding just over 6% again after the latest slump off 52-week highs of $11 and change. Indeed, it’s been a painful 14% correction in the name as investors re-evaluate where interest rates will be headed next. Despite the magnitude of the decline, I still view H&R as one of the cheapest ways to land a yield of around 6%. Unlike with SmartCentres, H&R REIT reduced its distribution during the pandemic. Despite this, the distribution has still been bountiful. And while it has been tough to sustain momentum after imploding back in 2020, I still think the diversified REIT, which has been offloading assets in recent quarters, stands out as one of the cheapest high-income offerings in the entire REIT scene. Sure, pressures facing the REIT may not subside anytime soon. But if you’re looking for passive income and in a single name, I think it’s tough to overlook HR.UN while it’s in the single digits again.NEW YORK — Technology stocks pulled Wall Street to another record amid a mixed Monday of trading. The S&P 500 rose 0.2% from its all-time high set Friday to post a record for the 54th time this year. The Dow Jones Industrial Average fell 128 points, or 0.3%, while the Nasdaq composite gained 1%. Super Micro Computer, a stock that’s been on an AI-driven roller coaster, soared 28.7% to lead the market. Following allegations of misconduct and the resignation of its public auditor, the maker of servers used in artificial-intelligence technology said an investigation found no evidence of misconduct by its management or by the company’s board. It also said it doesn’t expect to restate its past financials and that it will find a new chief financial officer, appoint a general counsel and make other moves to strengthen its governance. Big Tech stocks also helped prop up the market. Gains of 1.8% for Microsoft and 3.2% for Meta Platforms were the two strongest forces pushing upward on the S&P 500. Intel was another propellant during the morning, but it lost an early gain to fall 0.5% after the chip company said CEO Pat Gelsinger has retired and stepped down from the board. Intel is looking for Gelsinger’s replacement, and its chair said it’s “committed to restoring investor confidence.” Intel recently lost its spot in the Dow Jones Industrial Average to Nvidia, which has skyrocketed in Wall Street’s frenzy around AI. The majority of stocks in the S&P 500 fell, including California utility PG&E. It dropped 5% after saying it would sell $2.4 billion of stock and preferred shares to raise cash. Retailers were mixed amid what’s expected to be the best Cyber Monday on record and coming off Black Friday. Target fell 1.2%. Walmart rose 0.2%. Amazon, which looks to benefit from online sales from Cyber Monday, climbed 1.4%. All told, the S&P 500 added 14.77 points to 6,047.15. The Dow fell 128.65 to 44,782.00, and the Nasdaq composite climbed 185.78 to 19,403.95. The stock market largely took Donald Trump’s latest threat on tariffs in stride. The president-elect on Saturday threatened 100% tariffs against a group of developing economies if they act to undermine the U.S. dollar. Trump said he wants the group, headlined by Brazil, Russia, India and China, to promise it won’t create a new currency or otherwise try to undercut the U.S. dollar. The U.S. dollar’s value rose Monday against several other currencies, but one of its strongest moves likely had less to do with the tariff threats. The euro fell amid a political battle in Paris over the French government’s budget. The euro sank 0.7% against the U.S. dollar and broke below $1.05. In the bond market, Treasury yields gave up early gains to hold relatively steady. The yield on the 10-year Treasury ended the day at 4.19%. Get local news delivered to your inbox!

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)Liverpool shines in Champions League, dumping Real Madrid down the table. Dortmund rises to 4th

Brandon Crawford Retires After 14 MLB Seasons; Won 2 World Series Titles With GiantsENERGY SERVICES OF AMERICA COMPLETES ACQUISITION

The Michigan Wolverines pulled off one of the most shocking upsets of the 2024 college football season when they picked up a 13-10 victory over the Ohio State Buckeyes in Week 14. Unsurprisingly, all eyes have been on Ohio State's head coach Ryan Day in the wake of this defeat, which led to a hilarious take from Jalen Rose. Despite the fact that the Buckeyes entered this game as the No. 2 team in the nation, and the Wolverines were just 6-5, they managed to pull off an improbable win. It was not a very good look for Day, who has now lost four straight games to Michigan during his time in charge of Ohio State. Javascript is required for you to be able to read premium content. Thanks for the feedback.

Fianna Fail and Fine Gael eye independent TDs as option to secure Dail majorityNEW YORK (AP) — U.S. stocks are rising toward records Tuesday after Donald Trump’s latest talk about tariffs created only some ripples on Wall Street, even if they could roil the global economy were they to take effect. The S&P 500 climbed 0.5% and was on track to top its all-time high set a couple weeks ago. The Dow Jones Industrial Average added 81 points, or 0.2%, to its own record set the day before, while the Nasdaq composite was 0.5% higher, with less than an hour remaining in trading. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get any of our free email newsletters — news headlines, obituaries, sports, and more.By Michelle Marchante, Miami Herald (TNS) MIAMI — As her students finished their online exam, Arlet Lara got up to make a cafe con leche . Her 16-year-old son found her on the kitchen floor. First, he called Dad in a panic. Then 911. “I had a stroke and my life made a 180-degree turn,” Lara told the Miami Herald, recalling the medical scare she experienced in May 2020 in the early months of the COVID pandemic. “The stroke affected my left side of the body,” the North Miami woman and former high school math teacher said. Lara, an avid runner and gym goer, couldn’t even walk. “It was hard,” the 50-year-old mom said. After years of rehabilitation therapy and a foot surgery, Lara can walk again. But she still struggles with moving. This summer, she became the first patient in South Florida to get an implant of a new and only FDA-approved nerve stimulation device designed to help ischemic stroke survivors regain movement in their arms and hands. This first procedure was at Jackson Memorial Hospital in Miami. Lara’s rehab was at at the Christine E. Lynn Rehabilitation Center for The Miami Project to Cure Paralysis, part of a partnership between Jackson Health System and UHealth. Every year, thousands in the United States have a stroke , with one occurring every 40 seconds, according to the U.S. Centers for Disease Control and Prevention. The majority of strokes are ischemic, often caused by blood clots that obstruct blood flow to the brain. For survivors, most of whom are left with some level of disability, the Vivistim Paired VNS System, the device implanted in Lara’s chest, could be a game changer in recovery, said Dr. Robert Starke, a UHealth neurosurgeon and interventional neuroradiologist. He also serves as co-director of endovascular neurosurgery at Jackson Memorial Hospital, part of Miami-Dade’s public hospital system. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant designed to help stroke survivors regain function in their arms, goes through exercises while her therapist activates the device during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA- approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) The Vivistim Paired VNS System is a small pacemaker-like device implanted in the upper chest and neck area. Patients can go home the same day. The U.S. Food and Drug Administration approved the stroke rehabilitation system in 2021 to be used alongside post-ischemic stroke rehabilitation therapy to treat moderate to severe mobility issues in hands and arms. Lara’s occupational therapist can activate the device during rehabilitation sessions to electrically stimulate the vagus nerve, which runs from the brain down to the abdomen and regulates various parts of the body’s nervous system. The electrical stimulation rewires the brain to improve a stroke survivor’s ability to move their arms and hands. Lara also has a magnet she can use to activate the device when she wants to practice at home. Her therapy consists of repetitive tasks, including coloring, pinching cubes and grabbing and releasing cylindrical shapes. After several weeks of rehabilitation therapy with the device, Lara has seen improvement. “Little by little, I’m noticing that my hand is getting stronger. I am already able to brush my teeth with the left hand,” she told the Miami Herald in September. Since then, Lara has finished the initial six-week Vivitism therapy program, and is continuing to use the device in her rehabilitation therapy. She continues to improve and can now eat better with her left hand and can brush her hair with less difficulty, according to her occupational therapist, Neil Batungbakal. Lara learned about the device through an online group for stroke survivors and contacted the company to inquire. She then connected them with her Jackson medical team. Now a year later, the device is available to Jackson patients. So far, four patients have received the implant at Jackson. Starke sees the device as an opportunity to help bring survivors one step closer to regaining full mobility. Strokes are a leading cause of disability worldwide. While most stroke survivors can usually recover some function through treatment and rehabilitation, they tend to hit a “major plateau” after the first six months of recovery, he said. Vivistim, when paired with rehabilitation therapy, could change that. Jackson Health said results of a clinical trial published in the peer-reviewed medical journal The Lancet in 2021 showed that the device, “when paired with high-repetition, task-specific occupational or physical therapy, helps generate two to three times more hand and arm function for stroke survivors than rehabilitation therapy alone.” The device has even shown to benefit patients 20 years from their original stroke, according to Starke. “So now a lot of these patients that had strokes 10-15 years ago that thought that they would never be able to use their arm in any sort of real functional way are now able to have a real meaningful function, which is pretty tremendous,” Starke said. Vivistim’s vagus-nerve stimulation technology was developed by researchers at the University of Texas at Dallas’ Texas Biomedical Device Center and is being sold commercially by Austin-based MicroTransponder, a company started by university graduates. Similar devices are used to treat epilepsy and depression . For Lara, the device is a new tool to help her recovery journey. “Everything becomes a challenge so we are working with small things every day because I want to get back as many functions as possible,” Lara said. Patients interested in Vivistim should speak with their doctor to check their eligibility. The FDA said patients should make sure to discuss any prior medical history, including concurrent forms of brain stimulation, current diathermy treatment, previous brain surgery, depression, respiratory diseases and disorders such as asthma, and cardiac abnormalities. “Adverse events included but were not limited to dysphonia (difficulty speaking), bruising, falling, general hoarseness, general pain, hoarseness after surgery, low mood, muscle pain, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue,” the FDA said. MicroTransponder says the device is “covered by Medicare, Medicaid, and private insurance with prior authorization on a case-by-case basis.” To learn more about the device, visit vivistim.com. ©2024 Miami Herald. Visit at miamiherald.com. Distributed by Tribune Content Agency, LLC.

Geoffrey Hinton to donate some of Nobel winnings to create new annual awardTechnology stocks helped pull stocks lower on Wall Street Wednesday, handing the market its first loss in more than a week. The S&P 500 fell 0.4%, even though more stocks in the index notched gains than ended lower. The loss snapped a seven-day winning streak for the benchmark index. The Dow Jones Industrial Average fell 0.3%, its first loss after five gains. The Dow and S&P 500 remain near the all-time highs they set on Tuesday. The Nasdaq composite, which is heavily weighted with technology stocks, fell 0.6%. Losses for tech heavyweights like Nvidia, Microsoft and Broadcom were the drag on the market. Semiconductor giant Nvidia fell 1.2%. Its huge value gives it outsized influence on market indexes. Microsoft fell 1.2% and Broadcom finished 3.1% lower. Several personal computer makers also helped pull the market lower following their latest earnings reports. HP sank 11.4% after giving investors a weaker-than-expected earnings forecast for its current quarter. Dell slid 12.2% after its latest quarterly revenue fell short of Wall Street forecasts. Gains for financial and health care companies helped temper the market's losses. Berkshire Hathaway rose 0.9% and Merck & Co. added 1.5%. All told, the S&P 500 fell 22.89 points to 5,998.74, while the Dow dropped 138.25 points to 44,722.06. The Nasdaq fell 115.10 points to 19,060.48. Traders also had their eye on new reports on the economy and inflation Wednesday. The U.S. economy expanded at a healthy 2.8% annual pace from July through September, according to the Commerce Department, leaving its original estimate of third-quarter growth unchanged. The growth was driven by strong consumer spending and a surge in exports. The update followed a report on Tuesday from the Conference Board that said confidence among U.S. consumers improved in November, but not by as much as economists expected. Consumers have been driving economic growth, but the latest round of earnings reports from retailers shows a mixed and more cautious picture. Department store operator Nordstrom fell 8.1% after warning investors about a trend toward weakening sales that started in late October. Clothing retailer Urban Outfitters jumped 18.3% after beating analysts' third-quarter financial forecasts. Weeks earlier, retail giant Target gave investors a discouraging forecast for the holiday season, while Walmart provided a more encouraging forecast. Consumers, though resilient, are still facing pressure from inflation. The latest update from the U.S. government shows that inflation accelerated last month. The personal consumption expenditures index, or PCE, rose to 2.3% in October from 2.1% in September. Overall, the rate of inflation has been falling broadly since it peaked more than two years ago. The PCE, which is the Federal Reserve's preferred measure of inflation, was just below 7.3% in June of 2022. Another measure of inflation, the consumer price index, peaked at 9.1% at the same time. The latest inflation data, though, is a sign that the rate of inflation seems to be stalling as it falls to within range of the Fed's target of 2%. The central bank started raising its benchmark interest rate from near-zero in early 2022 to a two-decade high by the middle of 2023 and held it there in order to tame inflation. The Fed started cutting its benchmark interest rate in September, followed by a second cut in November. Wall Street expects a similar quarter-point cut at the central bank's upcoming meeting in December. "Today's data shouldn't change views of the likely path for disinflation, however bumpy," said David Alcaly, lead macroeconomic strategist at Lazard Asset Management. "But a lot of observers, probably including some at the Fed, are looking for reasons to get more hawkish on the outlook given the potential for inflationary policy change like new tariffs." President-elect Donald Trump has said he plans to impose sweeping new tariffs on Mexico, Canada and China when he takes office in January. That could shock the economy by raising prices on a wide range of goods and accelerating the rate of inflation. Such a shift could prompt the Fed to rethink future cuts to interest rates. Treasury yields slipped in the bond market. The yield on the 10-year Treasury fell to 4.25% from 4.30% late Tuesday. The yield on the two-year Treasury, which more closely follows expected actions by the Fed, fell to 4.22% from 4.25% late Tuesday. U.S. markets will be closed Thursday for Thanksgiving, and will reopen for a half day on Friday.

None

Toronto Argonauts sign American running back Kevin Brown